ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
Lastly
|
22 |
6.8K |
13 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
22
|
6.8K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
Lastly
|
148 |
31K |
11 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
148
|
31K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
Lastly
|
19 |
5.9K |
7 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
19
|
5.9K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
Lastly
|
19 |
5.9K |
0 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
19
|
5.9K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
Lastly
|
85 |
20K |
17 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
85
|
20K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Lastly
|
63 |
19K |
4 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
63
|
19K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Change of Registered Office and Principal Place of Business
|
|
Lastly
|
17 |
4.3K |
5 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
17
|
4.3K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Lastly
|
510 |
117K |
13 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
510
|
117K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Lastly
|
510 |
117K |
10 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
510
|
117K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Pharmaust Investor Update
|
|
Lastly
|
20 |
5.5K |
12 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
20
|
5.5K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Lastly
|
510 |
117K |
22 |
26/05/24 |
26/05/24 |
ASX - By Stock
|
510
|
117K
|
22
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Lastly
|
510 |
117K |
34 |
26/05/24 |
26/05/24 |
ASX - By Stock
|
510
|
117K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
Lastly
|
58 |
15K |
26 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
58
|
15K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Lastly
|
510 |
117K |
9 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
510
|
117K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Price manipulation
|
|
Lastly
|
35 |
8.1K |
0 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
35
|
8.1K
|
0
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Lastly
|
510 |
117K |
13 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
510
|
117K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Lastly
|
510 |
117K |
13 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
Lastly
|
58 |
15K |
11 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
58
|
15K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
3 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Lastly
|
86 |
20K |
9 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
Lastly
|
86 |
20K |
4 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Lastly
|
42 |
9.4K |
8 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
42
|
9.4K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
Lastly
|
42 |
9.4K |
4 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
42
|
9.4K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Lastly
|
250 |
62K |
16 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
250
|
62K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Lastly
|
250 |
62K |
15 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
62K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Lastly
|
250 |
62K |
21 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
62K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Lastly
|
250 |
62K |
23 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
250
|
62K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Lastly
|
250 |
62K |
12 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
250
|
62K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Lastly
|
250 |
62K |
14 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
250
|
62K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
Lastly
|
250 |
62K |
31 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
250
|
62K
|
31
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Lastly
|
83 |
24K |
5 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
83
|
24K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Lastly
|
83 |
24K |
11 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
83
|
24K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Lastly
|
104 |
20K |
4 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
20K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Lastly
|
239 |
64K |
18 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
239
|
64K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Lastly
|
239 |
64K |
17 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
239
|
64K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Lastly
|
104 |
20K |
6 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
104
|
20K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
Lastly
|
104 |
20K |
8 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
104
|
20K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Lastly
|
261 |
71K |
7 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
261
|
71K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
8 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Lastly
|
261 |
71K |
9 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
71K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Lastly
|
261 |
71K |
9 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
71K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
Lastly
|
100 |
27K |
15 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
100
|
27K
|
15
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
11 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
8 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
21 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
6 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
8 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
3 |
14/04/24 |
14/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
13 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Lastly
|
1.4K |
359K |
9 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
9
|
|